Comment on 'Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017'
Drug Saf. 2019 May;42(5):689-691.
doi: 10.1007/s40264-019-00814-5.